Lazaro Tyler, Brastianos Priscilla K
Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Boston, MA 02144, USA.
Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital, Boston, MA 02144, USA.
CNS Oncol. 2017 Apr;6(2):139-151. doi: 10.2217/cns-2016-0038.
Brain metastases (BM) continue to represent an unmet clinical need in oncology. Immunotherapy and targeted therapy hold great promise in the treatment of BM. Emerging data are confirming the activity of these agents in patients with BM. Genomic studies have confirmed that clinically actionable mutations are present in BM and they can be used in clinical studies to link targeted therapies with their genetic targets. Furthermore, as molecular signatures associated with sensitivity and resistance to immunotherapies are developed, we will better be able to select BM patients who will most benefit from these therapies. Understanding the genetic and immune evolution within BM should drive the next generation of immunotherapy and target therapy, as well as increase the accuracy of the selection process for these therapies.
脑转移瘤（BM）在肿瘤学领域仍然是尚未满足的临床需求。免疫疗法和靶向疗法在BM治疗中具有巨大潜力。新出现的数据证实了这些药物在BM患者中的活性。基因组研究已证实BM中存在具有临床可操作性的突变，这些突变可用于临床研究，将靶向疗法与其基因靶点联系起来。此外，随着与免疫疗法敏感性和耐药性相关的分子特征的发展，我们将能够更好地选择最能从这些疗法中获益的BM患者。了解BM内的基因和免疫进化应推动下一代免疫疗法和靶向疗法的发展，并提高这些疗法选择过程的准确性。
